REPLIGEN CORP (RGEN) Fundamental Analysis & Valuation

NASDAQ:RGEN • US7599161095

Current stock price

132.7 USD
+0.71 (+0.54%)
At close:
132.7 USD
0 (0%)
After Hours:

This RGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. RGEN Profitability Analysis

1.1 Basic Checks

  • RGEN had positive earnings in the past year.
  • RGEN had a positive operating cash flow in the past year.
  • Of the past 5 years RGEN 4 years were profitable.
  • RGEN had a positive operating cash flow in each of the past 5 years.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • RGEN's Return On Assets of 1.66% is fine compared to the rest of the industry. RGEN outperforms 69.64% of its industry peers.
  • RGEN has a better Return On Equity (2.32%) than 71.43% of its industry peers.
  • RGEN has a Return On Invested Capital of 1.65%. This is in the better half of the industry: RGEN outperforms 62.50% of its industry peers.
  • RGEN had an Average Return On Invested Capital over the past 3 years of 1.45%. This is significantly below the industry average of 11.80%.
  • The 3 year average ROIC (1.45%) for RGEN is below the current ROIC(1.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROIC 1.65%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 4 6 8

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.62%, RGEN is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
  • RGEN's Profit Margin has declined in the last couple of years.
  • The Operating Margin of RGEN (8.03%) is better than 67.86% of its industry peers.
  • RGEN's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 52.65%, RGEN is doing good in the industry, outperforming 66.07% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RGEN has declined.
Industry RankSector Rank
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RGEN Health Analysis

2.1 Basic Checks

  • RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for RGEN has been increased compared to 1 year ago.
  • RGEN has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RGEN has been reduced compared to a year ago.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • RGEN has an Altman-Z score of 6.26. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.26, RGEN belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
  • RGEN has a debt to FCF ratio of 5.91. This is a neutral value as RGEN would need 5.91 years to pay back of all of its debts.
  • RGEN has a better Debt to FCF ratio (5.91) than 71.43% of its industry peers.
  • RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • RGEN's Debt to Equity ratio of 0.26 is in line compared to the rest of the industry. RGEN outperforms 53.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Altman-Z 6.26
ROIC/WACC0.15
WACC10.95%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 8.37 indicates that RGEN has no problem at all paying its short term obligations.
  • RGEN has a better Current ratio (8.37) than 94.64% of its industry peers.
  • A Quick Ratio of 7.12 indicates that RGEN has no problem at all paying its short term obligations.
  • RGEN has a better Quick ratio (7.12) than 91.07% of its industry peers.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 7.12
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.54% over the past year.
  • RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.60% yearly.
  • Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -6.05% in the last year.
  • RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.05% yearly.
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%

3.2 Future

  • RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.07% yearly.
  • Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.56% on average per year.
EPS Next Y17.13%
EPS Next 2Y21.88%
EPS Next 3Y23.65%
EPS Next 5Y26.07%
Revenue Next Year12.85%
Revenue Next 2Y13.68%
Revenue Next 3Y14.21%
Revenue Next 5Y15.56%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

3

4. RGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 77.60, RGEN can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, RGEN is valued a bit cheaper than 60.71% of the companies in the same industry.
  • RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.66.
  • RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 66.26.
  • RGEN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. RGEN is cheaper than 60.71% of the companies in the same industry.
  • RGEN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 38.00.
Industry RankSector Rank
PE 77.6
Fwd PE 66.26
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
  • RGEN's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 81.63
EV/EBITDA 51.12
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of RGEN may justify a higher PE ratio.
  • RGEN's earnings are expected to grow with 23.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.53
PEG (5Y)130.36
EPS Next 2Y21.88%
EPS Next 3Y23.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGEN Dividend Analysis

5.1 Amount

  • RGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RGEN Fundamentals: All Metrics, Ratios and Statistics

REPLIGEN CORP

NASDAQ:RGEN (4/21/2026, 8:10:25 PM)

After market: 132.7 0 (0%)

132.7

+0.71 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners112.24%
Inst Owner Change0.08%
Ins Owners0.32%
Ins Owner Change-3.37%
Market Cap7.48B
Revenue(TTM)738.26M
Net Income(TTM)48.89M
Analysts81.43
Price Target191.89 (44.6%)
Short Float %10.46%
Short Ratio6.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.52%
Min EPS beat(2)7.78%
Max EPS beat(2)9.25%
EPS beat(4)3
Avg EPS beat(4)5.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)5
Avg EPS beat(8)5.28%
EPS beat(12)8
Avg EPS beat(12)7.82%
EPS beat(16)12
Avg EPS beat(16)10.63%
Revenue beat(2)2
Avg Revenue beat(2)1.33%
Min Revenue beat(2)0.58%
Max Revenue beat(2)2.07%
Revenue beat(4)4
Avg Revenue beat(4)1.51%
Min Revenue beat(4)0.58%
Max Revenue beat(4)2.15%
Revenue beat(8)4
Avg Revenue beat(8)-0.01%
Revenue beat(12)4
Avg Revenue beat(12)-0.88%
Revenue beat(16)7
Avg Revenue beat(16)0.5%
PT rev (1m)0.19%
PT rev (3m)-1.02%
EPS NQ rev (1m)-0.02%
EPS NQ rev (3m)-13.2%
EPS NY rev (1m)0.58%
EPS NY rev (3m)-4.92%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.65%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.36%
Valuation
Industry RankSector Rank
PE 77.6
Fwd PE 66.26
P/S 10.14
P/FCF 81.63
P/OCF 63.74
P/B 3.55
P/tB 12.36
EV/EBITDA 51.12
EPS(TTM)1.71
EY1.29%
EPS(NY)2
Fwd EY1.51%
FCF(TTM)1.63
FCFY1.23%
OCF(TTM)2.08
OCFY1.57%
SpS13.09
BVpS37.34
TBVpS10.74
PEG (NY)4.53
PEG (5Y)130.36
Graham Number37.9046 (-71.44%)
Profitability
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROCE 2.11%
ROIC 1.65%
ROICexc 2.27%
ROICexgc 8.52%
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
FCFM 12.42%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
ROICexc(3y)2.01%
ROICexc(5y)5.28%
ROICexgc(3y)7.46%
ROICexgc(5y)30.51%
ROCE(3y)1.85%
ROCE(5y)4.75%
ROICexgc growth 3Y-45.78%
ROICexgc growth 5YN/A
ROICexc growth 3Y-39.51%
ROICexc growth 5Y-19.39%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Debt/EBITDA 3.93
Cap/Depr 32.68%
Cap/Sales 3.49%
Interest Coverage 250
Cash Conversion 85.06%
Profit Quality 187.52%
Current Ratio 8.37
Quick Ratio 7.12
Altman-Z 6.26
F-Score6
WACC10.95%
ROIC/WACC0.15
Cap/Depr(3y)44.28%
Cap/Depr(5y)98.33%
Cap/Sales(3y)4.79%
Cap/Sales(5y)7.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
EPS Next Y17.13%
EPS Next 2Y21.88%
EPS Next 3Y23.65%
EPS Next 5Y26.07%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%
Revenue Next Year12.85%
Revenue Next 2Y13.68%
Revenue Next 3Y14.21%
Revenue Next 5Y15.56%
EBIT growth 1Y282.37%
EBIT growth 3Y-32.87%
EBIT growth 5Y-4.28%
EBIT Next Year81.31%
EBIT Next 3Y42.03%
EBIT Next 5Y37.01%
FCF growth 1Y-36.98%
FCF growth 3Y3.04%
FCF growth 5Y20.36%
OCF growth 1Y-33.06%
OCF growth 3Y-11.97%
OCF growth 5Y13.4%

REPLIGEN CORP / RGEN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 3 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


How profitable is REPLIGEN CORP (RGEN) stock?

REPLIGEN CORP (RGEN) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for RGEN stock?

The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 77.6 and the Price/Book (PB) ratio is 3.55.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 17.13% in the next year.